公开(公告)号：BRPI1006160A2

公开(公告)日：2016-02-23

申请号：BRPI1006160

申请日：2010-01-12

Applicant: UCB PHARMA SA

Inventor： LAWSON ALASTAIR DAVID GRIFFITHS

IPC: G01N33/68

公开(公告)号：MA37619A1

公开(公告)日：2016-01-29

申请号：MA37619

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: G01N33/53 ,  C07K16/28

Abstract: L'invention concerne des anticorps spécifiques de fcrn, des formulations les comprenant, l'utilisation de chacun en thérapie, des procédés d'expression et facultativement de formulations dudit anticorps, de l'adn codant pour les anticorps et des hôtes comprenant ledit adn..

公开(公告)号：TN2013000292A1

公开(公告)日：2015-01-20

申请号：TN2013000292

申请日：2013-07-10

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BAKER TERENCE SEWARD ,  LAWSON ALASTAIR DAVID GRIFFITHS

IPC: C07K16/24

公开(公告)号：CO7151521A2

公开(公告)日：2014-12-29

申请号：CO14272175

申请日：2014-12-11

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  G01N33/53

Abstract: ver pestaña anexos

公开(公告)号：PH12014502274B1

公开(公告)日：2014-12-10

申请号：PH12014502274

申请日：2014-10-09

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  G01N33/53

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：MX2014012890A

公开(公告)日：2014-11-14

申请号：MX2014012890

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： TYSON KERRY LOUISE ,  FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  G01N33/53

Abstract: La descripción se refiere a los anticuerpos específicos para FcRn, a las formulaciones que comprenden los mismos, el uso de cada uno en terapia, los procesos para expresar y para formar opcionalmente el anticuerpo, el ADN que codifica para los anticuerpos y hospederos que comprenden el ADN.

公开(公告)号：NZ594315A

公开(公告)日：2013-05-31

申请号：NZ59431510

申请日：2010-02-17

Applicant: UCB PHARMA SA

Inventor： LAWSON ALASTAIR DAVID GRIFFITHS ,  NESBITT ANDREW MALCOLM ,  POPPLEWELL ANDREW GEORGE ,  SHPEKTOR DIANA ,  ZHANG YI ,  SHAW STEVAN GRAHAM

IPC: C12N15/74 ,  A61K39/395 ,  A61P37/02 ,  C07H21/04 ,  C07K2/00 ,  C07K16/16 ,  C12N5/10 ,  C12P21/00

Abstract: 594315 Discloses an antibody which binds human OX40 comprising: CDR H1: NYGIH CDR H2: SISPSGGLTYYRDSVKG or SISPSGGLTYYRDSVEG CDR H3: GGEGIFDY CDR L1: RATQSIYNALA or RATEDIYNALA CDR L2: NANTLHT CDR L3 QQYYDYPLT For the treatment of allergies, COPD, asthma, autoimmune disease, or rheumatoid arthritis.

公开(公告)号：AU2012206431A1

公开(公告)日：2013-05-02

申请号：AU2012206431

申请日：2012-01-11

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BAKER TERENCE SEWARD ,  LAWSON ALASTAIR DAVID GRIFFITHS

IPC: C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：CA2780242A1

公开(公告)日：2011-05-26

申请号：CA2780242

申请日：2010-11-17

Applicant: UCB PHARMA SA

Inventor： HUMPHREYS DAVID PAUL ,  HEYWOOD SAM PHILIP ,  LAWSON ALASTAIR DAVID GRIFFITHS

IPC: C07K16/00 ,  C07K19/00

Abstract: A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally VH1, a CH1 region and a further variable domain nominally VH2, a light chain comprising, in sequence from the N-terminal, a variable domain nominally VL1, a CL domain and a variable domain nominally VL2, wherein said heavy and light chains are aligned to provide a first binding site formed by a first variable domain pair of VH1 and VL1 and a second binding site formed by a second variable domain pair of VH2 and VL2, wherein there is a disulfide bond between a variable domain pair forming a binding site, and said fusion protein is conjugated to a PEG polymer.

公开(公告)号：CA2778671A1

公开(公告)日：2011-05-05

申请号：CA2778671

申请日：2010-10-27

Applicant: UCB PHARMA SA

Inventor： MILLER KAREN MARGRETE ,  DE RYCK MARC ROGER ,  WOLFF CHRISTIAN GILBERT J ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  FINNEY HELENE MARGARET ,  BAKER TERENCE SEWARD

IPC: C07K16/28

Abstract: An anti- E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.